Ivana Djordjevic

Dr. Ivana Djordjevic

Center of pathology

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 November 2024 in Plants
Verified
Journal Article
Open access
PDF file
MMMilica Milutinović
Milica Milutinović
Nada Ćujić NikolićNada Ćujić Nikolić
Nada Ćujić Nikolić
TCTatjana Cvetković
Tatjana Cvetković
Katarina ŠavikinKatarina Šavikin
Katarina Šavikin
IDIvana Djordjevic
Ivana Djordjevic
DKDusanka Kitic
Dusanka Kitic
The study aimed to investigate the protective effects of chokeberry fruit products and by-products against cisplatin-induced acute nephrotoxicity in rats. Potential mechanisms involving oxidative stress and inflammatory responses were examined through biochemical and histopathological analyses of kidney tissue. Chokeberry waste, along with the whole fruit extract and juice, was evaluated as a potential raw material for pharmaceutical use. The chemical composition of chokeberry juice and extracts was analyzed using spectrophotometry and HPLC. Rats were treated with chokeberry preparations via intragastric tube for ten days, with a single intraperitoneal dose of cisplatin (8 mg/kg BW) administered on the third day. Post-sacrifice, plasma samples were analyzed for biochemical nephrotoxicity markers, oxidative stress, and inflammatory markers. Kidneys were removed for histopathological and biochemical analysis. Cisplatin-induced acute nephrotoxicity was confirmed by elevated plasma creatinine and blood urea nitrogen levels. Additionally, lipid peroxidation was significantly elevated, while reduced glutathione and catalase activity were significantly reduced. Pro-inflammatory mediators IL-1β, TNF-α, and IL-6 levels were significantly increased in the cisplatin group. Treatment with chokeberry extracts and juice significantly mitigated these nephrotoxic effects, as confirmed by histopathological examination and biochemical marker analysis. Notably, the waste extract demonstrated greater efficacy than the whole fruit extract, likely due to its higher concentration of polyphenolic compounds, especially anthocyanins. These results highlight the potential of chokeberry as a therapeutic and preventive agent for kidney protection, emphasizing the value of by-products rich in biologically active compounds.

27 April 2022 in Medicina
Verified
Journal Article
Open access
PDF file
ICIrena Gradislav Conic
Irena Gradislav Conic
BNBojan Nedovic
Bojan Nedovic
SSSlavica Stojnev
Slavica Stojnev
ITIlinka Živojin Todorovska
Ilinka Živojin Todorovska
ADAleksandra Dimitrijevic
Aleksandra Dimitrijevic
BDBiljana Djordjevic
Biljana Djordjevic
Background and Objectives: For stage IIIb–IV ovarian cancer, bevacizumab-containing treatment is considered the standard of care. The purpose of this study was to evaluate the efficacy of bevacizumab in combination with carboplatin and paclitaxel as a first-line treatment for advanced ovarian cancer. Materials and Methods: Eligible patients had stage IIIc–IV ovarian cancer according to the International Federation of Gynecology and Obstetrics with no clinical signs or symptoms of gastrointestinal obstruction or a history of abdominal fistulae, gastrointestinal perforation, or intra-abdominal abscess or evidence of rectosigmoid involvement by pelvic examination, bowel involvement on computed tomography, or clinical symptoms of bowel obstruction in the previous 6 months. After debulking surgery, the patients received 175 mg/m2 paclitaxel and carboplatin (AUC 6) for the first six cycles and 7.5 mg/kg bevacizumab every three weeks up to 17 cycles until disease progression, unacceptable toxicity, or consent withdrawal. The primary endpoint was progression-free survival. The secondary endpoint was overall survival. Results: Between April 2017 and March 2020, 35 patients began study treatment. Bevacizumab was administered at 7.5 mg/kg in all the patients and for more than 7.5 months in 70% of them. The median progression-free survival was 20 months (95% CI: 16–23). The median overall survival was not reached. Conclusions: This was, to our knowledge, the first trial in Serbia to show progression-free survival and overall survival of combination regimens in advanced ovarian cancer. Based on the observed progression-free survival, bevacizumab combined with chemotherapy should be considered as a standard option in advanced ovarian cancer.

4 July 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
Ivan Ratko IlicIvan Ratko Ilic
Ivan Ratko Ilic
Pavle RandjelovicPavle Randjelovic
Pavle Randjelovic
Ilija GolubovicIlija Golubovic
Ilija Golubovic
MLMilan Vladimir Lazarevic
Milan Vladimir Lazarevic
MJMaja Jovicic-Milentijevic
Maja Jovicic-Milentijevic
MVMilica Veljković
Milica Veljković
Background/Objectives: Colorectal serrated lesions are highly heterogeneous at the micromorphological level. Their morphology can range from seemingly harmless, as in the case of hyperplastic polyps with little to no neoplastic potential, to lesions that can undergo malignant transformation within a short period of time. The serrated morphology of these lesions is primarily a consequence of morphological changes resulting from the enlargement and budding of the adenoma, as well as the migration of its epithelium at the crypt level. This creates elevations that resemble saw teeth. In this study, the serrated morphology was highlighted immunohistochemically using the MUC2 marker. Results: MUC5AC immunohistochemical expression exhibited greater variability in positivity and intensity compared to MUC2 expression. Pancryptic MUC5AC positivity was present in 75% of TSA cases and in 75% of malignantly transformed serrated lesions. This correlates with advanced histologic lesions and dysplasia development within the serrated pathway of carcinogenesis. MUC5AC is a useful marker for detecting polyps undergoing malignant transformation but not for distinguishing between sessile serrated lesions and hyperplastic polyps. Analysis of Ki-67 proliferative activity in serrated lesions in this study showed that a shift in the proliferative zone along the entire crypt was statistically significant only in TSA (p < 0.01). p53 expression increases from low-grade to high-grade dysplasia and malignant transformation of serrated lesions. This study confirmed that p53 expression in the upper half of the crypt was present in 11% of sessile serrated lesions without dysplasia and in 18% with dysplasia. In malignantly transformed serrated lesions, pancryptic positivity was present in 25% of cases. Conclusions: A marker panel consisting of mucin glycoproteins, Ki-67, and p53 could be useful in assessing the risk level of malignant transformation in serrated lesions.